The Role of 18F-FDG PET in Staging and Early Prediction of Response to Therapy of Recurrent Gastrointestinal Stromal Tumors

摘要: Gastrointestinal stromal tumors (GISTs) are gaining the interest of researchers because impressive metabolic response to targeted molecular therapeutic drug imatinib mesylate. Initial reports suggest an role for 18F-FDG PET in follow-up therapy these tumors. However, versus that CT has not been established. Therefore, we compared roles and staging evaluation early mesylate recurrent or metastatic GIST. Methods: The study included 54 patients who underwent scans within 3 wk before initiation therapy. Forty-nine repeat 2 mo after numbers sites organs containing lesions on were compared. Corresponding those confirmed be malignant appearance by other imaging modalities considered true positives. Lesions seen but benign with false Measurements maximum standard uptake value (SUV) tumor size used quantitative Results: A total 122 114 and/or involved pretherapy scans, respectively. sensitivity positive predictive values (PPVs) 93% 100%; whereas 86% 98%. differences between statistically significant (P = 0.27 0.25 PPV). This suggests comparable performance GISTs. Repeat at showed agreement 71.4% (57.1% having a good 14.3% lacking response). Discrepant results recorded 28.6% patients. predicted earlier than did 22.5% during longer interval (4–16 mo), lack 4.1%. One patient undergo long-term follow-up. These findings is superior predicting GIST Conclusion: performances GISTs Thus, better guide